GlobeNewswire by notified

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Share

Regulated Information - Denominator

Atlas Special Opportunities, LLChas converted 6convertible bonds in Oxurion resulting in a EUR 150,000capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.

Leuven, BELGIUM,Boston, MA, US September 18, 202308.00 AM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 116,459,627 new ordinary shares on September 15, 2023, for a total amount of EUR 150,000, as the result of the conversion of 6 convertible bonds, pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.

Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,667,771,604 outstanding ordinary shares carrying voting rights (compared to 2,551,311,977 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

  • Share capital (EUR)
82,756,161.32

  • Total number of securities with voting rights (all ordinary shares)
2,667,771,604
  • Total number of ordinary shares (= denominator)
2,667,771,604
  • Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
  • 590,500 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 590,500 securities carrying voting rights (all ordinary shares);
  • 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
  • 972,250 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 972,250 securities carrying voting rights (all ordinary shares);
  • 532,500 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 532,500 securities carrying voting rights (all ordinary shares);
  • 604,405 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 604,405 securities carrying voting rights (all ordinary shares);
  • 190 convertible bonds issued on March 14, 2023, April 20, 2023, May 22, 2023, June 15, 2023, August 10, 2023, and September 15, 2023, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities, LLC on March 1, 2023; and
  • 100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021 (as amended from time to time).

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com



Michaël Dillen
Chief Business Officer
Tel: +32 16 75 13 10
michael.dillen@oxurion.com
US
Conway Communications
Mary T. Conway
mtconway@conwaycommsir.com





1Press release Oxurion, 02/03/2023

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Northland Power Announces Appointment of Ellen Smith to Its Board of Directors30.11.2023 00:09:14 CET | Press release

TORONTO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) announces the expansion of its Board of Directors from nine to ten members and the appointment of Ellen Smith as a Director, effective November 29, 2023. Ms. Smith brings over 35 years of leadership experience within the power and utilities sector. After spending her early career at original equipment manufacturers GE Power Systems and Pratt & Whitney, Ms. Smith led a co-gen business initiative and power & utilities facilities at a refinery of Hess Corp., and led U.S. Operations at National Grid, which included gas and electric transmission and distribution, LNG operations and power generation. For the last decade, Ms. Smith has been the Senior Managing Director at FTI Consulting, where she advises clients on strategy operational issues, and corporate finance, with a focus on power and utilities and EPC clients. Ms. Smith serves as an expert in complex power and utilities litigatio

Constellation Brands to Present at the 2023 Morgan Stanley Global Consumer and Retail Conference on December 5, 202329.11.2023 22:30:33 CET | Press release

VICTOR, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 2023 Morgan Stanley Global Consumer and Retail Conference on Tuesday, December 5, 2023 in New York, NY. The presentation is scheduled to begin at 1:30 p.m. ET and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non-GAAP financial measures, will also be available on the company’s investor relations website under t

CNH Industrial: Periodic Report on $1 Billion Buyback Program29.11.2023 22:30:00 CET | Press release

Basildon, November 29, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that under the €400 million component (the “First Component”) of its $1 billion share buyback program the Company completed transactions in the period November 20, 2023 through November 24, 2023, reported in aggregate, as set forth in the table below. After the purchases announced today and considering those previously executed under the First Component, the total invested amount in the First Component is approximately €163,979,188.20 ($177,525,418.19) or a total amount of 17,560,075 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (*) excluding fees(€)(€)($) November 20, 2023 473,000 9.5539 4,518,994.70 4,938,357.41 November 21, 2023 2,190,000 9.2275 20,208,225.00 22,138,110.49 November 22, 2023 1,494,075 9.1293 13,639,858.90 14,882,450.04 November 23, 2023 1,000,000 9.1982 9,198,200.00 10,026,038.00 November 24

nCino Reports Third Quarter Fiscal Year 2024 Financial Results29.11.2023 22:05:00 CET | Press release

Total Revenues of $121.9M, up 16% year-over-year Subscription Revenues of $104.8M, up 19% year-over-yearGAAP Operating Margin of (11)%, up 700 basis points year-over-yearNon-GAAP Operating Margin of 17%, up 1,400 basis points year-over-year WILMINGTON, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced financial results for the third quarter of fiscal year 2024, ended October 31, 2023. “We posted another solid quarter in Q3, with revenues and profitability again exceeding expectations,” said Pierre Naudé, Chairman and CEO of nCino. “Notably, we added key new customers, such as our first enterprise Consumer ending deal with a $200 billion bank in the U.S., and our largest customer to date in Japan. We are also pleased that our U.S. mortgage business achieved double-digit revenue growth despite generationally-high interest rates." Naudé continued, "With years of experience successfully

Torqx declares offer for Beter Bed Holding unconditional; 95.14% of Shares now tendered or committed29.11.2023 20:15:00 CET | Press release

JOINT PRESS RELEASE This is a joint press release by Beter Bed Holding N.V. ("Beter Bed Holding" or the "Company") and 959 B.V. (the "Offeror"), a company controlled by Torqx Capital Partners ("Torqx"). This joint press release is issued pursuant to the Article 16, paragraphs 1 and 2, Article 17 paragraph 1 and Article 4, paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the "Decree") in connection with the recommended public offer by the Offeror for all the issued and outstanding shares in the capital of the Company (the "Offer"). This press release does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in the Company. Any offer is only made by means of the offer memorandum (the "Offer Memorandum"), dated 4 October 2023, approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten, the "AFM"). Terms not defined in this press release will have the meaning as set fort